S&P 500   2,986.20 (-0.39%)
DOW   26,770.20 (-0.95%)
QQQ   191.69 (-0.96%)
AAPL   236.41 (+0.48%)
FB   185.85 (-2.38%)
MSFT   137.41 (-1.63%)
GOOGL   1,244.41 (-0.67%)
AMZN   1,757.51 (-1.68%)
CGC   20.21 (-2.65%)
NVDA   190.49 (-1.96%)
MU   43.47 (-4.46%)
BABA   169.13 (-4.37%)
GE   8.96 (-0.88%)
TSLA   256.95 (-1.92%)
AMD   30.97 (-0.55%)
T   38.47 (+1.75%)
F   9.29 (+1.98%)
ACB   3.68 (-5.40%)
PRI   123.53 (-0.44%)
NFLX   275.30 (-6.15%)
BAC   30.35 (+0.30%)
GILD   64.91 (-0.49%)
DIS   130.89 (-1.12%)
S&P 500   2,986.20 (-0.39%)
DOW   26,770.20 (-0.95%)
QQQ   191.69 (-0.96%)
AAPL   236.41 (+0.48%)
FB   185.85 (-2.38%)
MSFT   137.41 (-1.63%)
GOOGL   1,244.41 (-0.67%)
AMZN   1,757.51 (-1.68%)
CGC   20.21 (-2.65%)
NVDA   190.49 (-1.96%)
MU   43.47 (-4.46%)
BABA   169.13 (-4.37%)
GE   8.96 (-0.88%)
TSLA   256.95 (-1.92%)
AMD   30.97 (-0.55%)
T   38.47 (+1.75%)
F   9.29 (+1.98%)
ACB   3.68 (-5.40%)
PRI   123.53 (-0.44%)
NFLX   275.30 (-6.15%)
BAC   30.35 (+0.30%)
GILD   64.91 (-0.49%)
DIS   130.89 (-1.12%)
Log in

AVITA MED LTD/S Stock Price, News & Analysis (OTCMKTS:AVMXY)

$7.47
-0.42 (-5.32 %)
(As of 10/1/2019)
Today's Range
$7.25
Now: $7.47
$8.34
50-Day Range
$5.96
MA: $7.39
$8.26
52-Week Range
$1.06
Now: $7.47
$8.58
Volume202,352 shs
Average Volume183,275 shs
Market Capitalization$617.17 million
P/E RatioN/A
Dividend YieldN/A
Beta1.28
Avita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It offers regenerative products for the treatment of burns, chronic wounds, and aesthetics indications. The company's patented and proprietary collection and application technology provides treatment solutions derived from a patient's own skin. Its lead product, RECELL System, is used in the treatment of various skin defects, such as burns and plastic reconstructive procedures. The company also offers ReGenerCell for chronic wounds and ReNovaCell for the restoration of pigmentation. Avita Medical Limited is based in Valencia, California.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:AVMXY
CUSIPN/A
CIKN/A
Phone661-367-9170

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.51 million
Book Value$0.26 per share

Profitability

Miscellaneous

Employees55
Market Cap$617.17 million
Next Earnings DateN/A
OptionableNot Optionable

Receive AVMXY News and Ratings via Email

Sign-up to receive the latest news and ratings for AVMXY and its competitors with MarketBeat's FREE daily newsletter.


AVITA MED LTD/S (OTCMKTS:AVMXY) Frequently Asked Questions

What is AVITA MED LTD/S's stock symbol?

AVITA MED LTD/S trades on the OTCMKTS under the ticker symbol "AVMXY."

What price target have analysts set for AVMXY?

1 brokerages have issued 1-year price objectives for AVITA MED LTD/S's shares. Their forecasts range from $10.00 to $10.00. On average, they expect AVITA MED LTD/S's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 33.9% from the stock's current price. View Analyst Price Targets for AVITA MED LTD/S.

What is the consensus analysts' recommendation for AVITA MED LTD/S?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVITA MED LTD/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AVITA MED LTD/S.

Has AVITA MED LTD/S been receiving favorable news coverage?

News headlines about AVMXY stock have trended neutral this week, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AVITA MED LTD/S earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave news coverage about the medical device company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for AVITA MED LTD/S.

Who are some of AVITA MED LTD/S's key competitors?

What other stocks do shareholders of AVITA MED LTD/S own?

Who are AVITA MED LTD/S's key executives?

AVITA MED LTD/S's management team includes the folowing people:
  • Dr. Michael S. Perry, CEO & Director (Age 60)
  • Mr. Timothy Rooney, Chief Admin. Officer & Interim CFO
  • Mr. Andrew Quick, Chief Technology Officer
  • Ms. Erin Liberto, Chief Commercial Officer
  • Mr. Adam Kelliher, Consultant

How do I buy shares of AVITA MED LTD/S?

Shares of AVMXY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is AVITA MED LTD/S's stock price today?

One share of AVMXY stock can currently be purchased for approximately $7.47.

How big of a company is AVITA MED LTD/S?

AVITA MED LTD/S has a market capitalization of $617.17 million and generates $5.51 million in revenue each year. The medical device company earns $-24,750,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. AVITA MED LTD/S employs 55 workers across the globe.View Additional Information About AVITA MED LTD/S.

What is AVITA MED LTD/S's official website?

The official website for AVITA MED LTD/S is http://www.avitamedical.com/.

How can I contact AVITA MED LTD/S?

AVITA MED LTD/S's mailing address is 28159 Avenue Stanford Suite 220, Valencia CA, 91355. The medical device company can be reached via phone at 661-367-9170 or via email at [email protected]


MarketBeat Community Rating for AVITA MED LTD/S (OTCMKTS AVMXY)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  120 (Vote Outperform)
Underperform Votes:  89 (Vote Underperform)
Total Votes:  209
MarketBeat's community ratings are surveys of what our community members think about AVITA MED LTD/S and other stocks. Vote "Outperform" if you believe AVMXY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVMXY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel